EVH Stock Recent News

Evolent Health, Inc., is a mid-cap solutions provider in the healthcare space that made a major acquisition late last year. The stock is down some 30% from recent highs despite impressive sales growth and solid analyst firm support. Earnings will decline in FY2023 as the company integrates its new operations before rebounding significantly in FY2024.

WASHINGTON , Aug. 8, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced that Chief Executive Officer Seth Blackley, Chief Financial Officer John Johnson and Vice President, Investor Relations Seth Frank will participate in upcoming investor conferences, including meetings with institutional investors and presentations. A live audio-only webcast and replay for these events will be available, if applicable, on the Investor Relations section of Evolent's website at http://ir.evolenthealth.com.

Evolent Health, Inc. (NYSE:EVH ) Q2 2023 Earnings Conference Call August 2, 2023 5:00 PM ET Company Participants Seth Frank – Vice President-Investor Relations Seth Blackley – Chief Executive Officer John Johnson – Chief Financial Officer Conference Call Participants Jeff Garro – Stephens Sean Dodge – RBC Capital Ryan Daniels – William Blair Charles Rhyee – TD Cowan David Larsen – BTIG Sandy Draper – Guggenheim Jessica Tassan – Piper Sandler Richard Close – Canaccord Genuity Jailendra Singh – Truist Operator Welcome to the Evolent Earnings Conference Call for the Quarter Ending June 30, 2023. As a reminder, this conference call is being recorded.

Evolent Health: Business Economics Still Appealing, Reiterate Buy

Evolent Health, Inc. (NYSE:EVH ) Q1 2023 Results Conference Call May 3, 2023 5:00 PM ET Company Participants Seth Frank - VP, IR Seth Blackley - CEO John Johnson - CFO Conference Call Participants Sandy Draper - Guggenheim Partners Anne Samuel - JP Morgan Charles Rhyee - TD Cowen David Larsen - BTIG Jailendra Singh - Truist Jeff Garro - Stephens Jessica Tassan - Piper Sandler Richard Close - Canaccord Genuity Ryan Daniels - William Blair Sean Dodge - RBC Capital Markets Operator Welcome to Evolent Health's Earnings Conference Call for the Quarter Ended March 31, 2023. As a reminder, this conference call is being recorded.

Evolent Health (EVH) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.12 per share a year ago.

Nancy Prial, Essex Investments Management co-chief executive officer & senior portfolio manager, on Evolent Health with CNBC's Melissa Lee and the Fast Money traders.

WASHINGTON , March 3, 2023 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Chief Financial Officer John Johnson and Vice President, Investor Relations, Seth Frank will participate in upcoming investor conferences, including meetings with institutional investors and presentations. A live audio-only webcast and replay for these events will be available on the investor relations section of Evolent's website at ir.evolenthealth.com/, unless otherwise noted below.

Evolent Health, Inc. (NYSE:EVH ) Q4 2022 Earnings Conference Call February 22, 2023 5:00 PM ET Company Participants Seth Frank - Vice President, Investor Relations Seth Blackley - Chief Executive Officer John Johnson - Chief Financial Officer Conference Call Participants Sean Dodge - RBC Capital Markets Anne Samuel - JPMorgan Ryan Daniels - William Blair David Larsen - BTIG Sandy Draper - Guggenheim Richard Close - Canaccord Genuity Jailendra Singh - Truist Jessica Tassan - Piper Sandler Charles Rhyee - Cowen Operator Welcome to Evolent Health's Earnings Conference Call for the Fourth Quarter and Year ended December 31, 2022. As a reminder, this conference call is being recorded.

Evolent Health (EVH) delivered earnings and revenue surprises of 66.67% and 2.34%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?